Esperion upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Jessica Fye upgraded Esperion Therapeutics to Neutral from Underweight and raised her price target for the shares to $47 from $38. The analyst sees a “less bumpy year” for bempedoic acid.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.